{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse+Leukemia&page=4", "query": { "condition": "Relapse Leukemia", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 1827, "total_pages": 183, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse+Leukemia&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse+Leukemia&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T14:27:06.298Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05396859", "title": "Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Decitabine and Cedazuridine", "type": "DRUG" }, { "name": "Entrectinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2022-10-28", "completion_date": "2027-02-01", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-11-05T14:27:06.298Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05396859" }, { "nct_id": "NCT04887259", "title": "Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Multiple Myeloma", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "LAVA-051", "type": "BIOLOGICAL" }, { "name": "Interleukin 2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Lava Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2021-07-12", "completion_date": "2023-09-06", "has_results": false, "last_update_posted_date": "2025-01-27", "last_synced_at": "2026-11-05T14:27:06.298Z", "location_count": 5, "location_summary": "Atlanta, Georgia • New York, New York • Charlotte, North Carolina + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04887259" }, { "nct_id": "NCT03331198", "title": "Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia, Lymphocytic, Chronic, B-Cell", "Lymphoma, Small Lymphocytic" ], "interventions": [ { "name": "JCAR017 (lisocabtagene maraleucel)", "type": "BIOLOGICAL" }, { "name": "JCAR017 (lisocabtagene maraleucel) + ibrutinib", "type": "BIOLOGICAL" }, { "name": "JCAR017 (lisocabtagene maraleucel) + venetoclax", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Juno Therapeutics, a Subsidiary of Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2017-11-27", "completion_date": "2027-11-26", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-11-05T14:27:06.298Z", "location_count": 83, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03331198" }, { "nct_id": "NCT01656031", "title": "A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "clofarabine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 39, "start_date": "2005-02", "completion_date": "2008-11", "has_results": true, "last_update_posted_date": "2017-06-20", "last_synced_at": "2026-11-05T14:27:06.298Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01656031" }, { "nct_id": "NCT03162536", "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, B-Cell", "Small Lymphocytic Lymphoma", "Chronic Lymphocytic Leukemia", "Waldenstrom Macroglobulinemia", "Mantle Cell Lymphoma", "Diffuse Large B Cell Lymphoma", "Richter's Transformation", "Follicular Lymphoma", "Marginal Zone Lymphoma" ], "interventions": [ { "name": "Nemtabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 190, "start_date": "2017-06-26", "completion_date": "2027-09-17", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-11-05T14:27:06.298Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03162536" }, { "nct_id": "NCT02016729", "title": "A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignancy", "Cancer", "Oncology", "Oncology Patients", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "AMG 232", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kartos Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2014-04-01", "completion_date": "2017-07-31", "has_results": false, "last_update_posted_date": "2019-02-27", "last_synced_at": "2026-11-05T14:27:06.298Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Buffalo, New York • Charlotte, North Carolina + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Buffalo", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02016729" }, { "nct_id": "NCT00005592", "title": "Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "90-Y-ibritumomab tiuxetan", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "indium In 111 ibritumomab tiuxetan", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "1999-11", "completion_date": "2005-11", "has_results": false, "last_update_posted_date": "2015-10-21", "last_synced_at": "2026-11-05T14:27:06.298Z", "location_count": 2, "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005592" }, { "nct_id": "NCT04521231", "title": "A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B Cell Precursor Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Blinatumomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 181, "start_date": "2021-01-04", "completion_date": "2029-05-25", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-11-05T14:27:06.298Z", "location_count": 13, "location_summary": "Clovis, California • Duarte, California • Chicago, Illinois + 10 more", "locations": [ { "city": "Clovis", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04521231" }, { "nct_id": "NCT03144245", "title": "Study of AMV564 in Patients With AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "AMV564", "type": "BIOLOGICAL" }, { "name": "AMV564 in combination with pembrolizumab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "BIOLOGICAL", "COMBINATION_PRODUCT" ], "sponsor": "Amphivena Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2017-03-20", "completion_date": "2020-11-05", "has_results": false, "last_update_posted_date": "2021-10-12", "last_synced_at": "2026-11-05T14:27:06.298Z", "location_count": 10, "location_summary": "San Francisco, California • Chicago, Illinois • Baltimore, Maryland + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hawthorne", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03144245" }, { "nct_id": "NCT00076401", "title": "A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Leukemia, Lymphocytic, Chronic" ], "interventions": [ { "name": "Motexafin gadolinium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2014-06-26", "last_synced_at": "2026-11-05T14:27:06.298Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00076401" } ] }